Compare COOK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | GHRS |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.1M | 892.0M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | GHRS |
|---|---|---|
| Price | $1.08 | $12.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $2.04 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 924.1K | 235.7K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,799,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $6.85 |
| 52 Week High | $2.70 | $20.50 |
| Indicator | COOK | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 40.90 |
| Support Level | $1.00 | $12.04 |
| Resistance Level | $1.16 | $13.33 |
| Average True Range (ATR) | 0.10 | 0.79 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 78.37 | 19.50 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.